Exogenous Hormone Exposure (Iatrogenic Cushing's Syndrome)
The most likely cause of this patient's hypertension is exogenous hormone exposure from chronic prednisone therapy, which has induced iatrogenic Cushing's syndrome. 1
Clinical Reasoning
This patient presents with the classic triad that definitively points to glucocorticoid excess:
- 2-year history of daily prednisone use (the exogenous source) 1
- Cushingoid features: plethoric facies, supraclavicular fat pad deposition (buffalo hump), and widespread ecchymoses (easy bruising from skin fragility) 2, 1
- Severe hypertension (170/108 mm Hg) in the setting of these features 3, 2
The FDA label for prednisone explicitly lists "development of cushingoid state" and "hypertension or aggravation of hypertension" as adverse reactions, along with the exact physical findings this patient demonstrates: buffalo hump, moon face, ecchymoses and petechiae (bruising), and thin fragile skin. 1
Why Not the Other Options?
Immune complex nephropathy (lupus nephritis) would be a consideration in any SLE patient with hypertension, but the constellation of Cushingoid features makes this secondary to the more obvious glucocorticoid excess. 3 The physical examination findings are pathognomonic for Cushing's syndrome, not nephropathy alone.
Primary essential hypertension does not explain the characteristic Cushingoid physical findings. 3
Ectopic trophic hormone secretion and malignant glandular hormone secretion would represent endogenous Cushing's syndrome, but there is a clear exogenous source (prednisone) already present. 2 These would be considered only if the patient were not on chronic glucocorticoid therapy.
Pathophysiology of Glucocorticoid-Induced Hypertension
Hypertension occurs in 70-90% of patients with Cushing's syndrome (whether endogenous or exogenous). 3, 2 The mechanisms are multiple:
- Primary mechanism: Excess cortisol overwhelms the protective 11β-hydroxysteroid dehydrogenase type 2 enzyme, causing overstimulation of mineralocorticoid receptors and increased renal sodium absorption. 3, 4
- Additional pathways: Activation of the renin-angiotensin system, sensitization of vasculature to catecholamines, and impaired nitric oxide bioavailability. 2, 4
Management Approach
Immediate antihypertensive therapy should prioritize mineralocorticoid receptor antagonists (spironolactone or eplerenone) as the most effective agents, since they directly block the cortisol-mediated mineralocorticoid receptor activation that drives sodium retention. 3, 4, 5
Adequate diuretic therapy must be combined with mineralocorticoid receptor antagonists given the prominent role of volume expansion. 4, 5
Standard antihypertensive agents (ACE inhibitors, calcium channel blockers, beta-blockers) may not be effective alone because they don't address the underlying sodium retention mechanism. 4
Definitive treatment requires tapering or discontinuing the prednisone if clinically feasible for her SLE, though this must be balanced against her underlying disease activity. 5 After resolution of hypercortisolism, approximately 30% of patients have persistent hypertension requiring ongoing treatment. 6
Critical Pitfall
The cardiovascular mortality rate in Cushing's syndrome is four times that of the general population, making aggressive blood pressure control essential. 2, 6 The average diagnostic delay is 3 years, and attributing symptoms to other causes (in this case, potentially to SLE alone) prolongs exposure to cardiovascular risk. 2